Megakaryon is aiming for mass production of the first global iPSC (induced Pluripotent Stem Cell)-derived platelet product for allogeneic use. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed Dr. AKAMATSU Kenichi, CEO, and Mr. AYABE Tsuyoshi, COO & CFO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?